Literature DB >> 29353398

New Strategies of ARV: the Road to Simplification.

Rosa de Miguel Buckley1, Rocio Montejano1, Natalia Stella-Ascariz1, Jose R Arribas2,3.   

Abstract

PURPOSE OF REVIEW: Simplification of antiretroviral therapy is a strategy aiming to reduce pill burden, drug interactions, and toxicity. This review focuses on the most recent and important studies evaluating a reduction on the number of drugs for HIV treatment, both in naive and virologically suppressed patients. RECENT
FINDINGS: Interesting studies have been performed in the past years testing dual therapy and monotherapy, with variable rates of virological control. Novel therapeutics like immunotherapy or long-acting antiretrovirals can also be considered for simplification. Reducing the number of drugs for HIV treatment can be an option for selected patients. Current available evidence favors dual therapy over monotherapy. Future research should seek to identify the best candidates for simplification.

Entities:  

Keywords:  Antiretroviral therapy; Dual therapy; HIV; Monotherapy; Nucleoside sparing; Simplification

Mesh:

Substances:

Year:  2018        PMID: 29353398     DOI: 10.1007/s11904-018-0371-6

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  41 in total

1.  Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.

Authors:  P M Girard; A Antinori; J R Arribas; D Ripamonti; C Bicer; B Netzle-Sveine; B Hadacek; C Moecklinghoff
Journal:  HIV Med       Date:  2016-06-09       Impact factor: 3.180

Review 2.  Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.

Authors:  Amit C Achhra; Gwamaka Mwasakifwa; Janaki Amin; Mark A Boyd
Journal:  Lancet HIV       Date:  2016-05-31       Impact factor: 12.767

3.  Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Authors:  Simona Di Giambenedetto; Massimiliano Fabbiani; Eugenia Quiros Roldan; Alessandra Latini; Gabriella D'Ettorre; Andrea Antinori; Antonella Castagna; Giancarlo Orofino; Daniela Francisci; Pierangelo Chinello; Giordano Madeddu; Pierfrancesco Grima; Stefano Rusconi; Massimo Di Pietro; Annalisa Mondi; Nicoletta Ciccarelli; Alberto Borghetti; Emanuele Focà; Manuela Colafigli; Andrea De Luca; Roberto Cauda
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

4.  Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients.

Authors:  Ildefonso Pulido; Miguel Genebat; Ana I Alvarez-Rios; Rebeca S De Pablo-Bernal; Mohammed Rafii-El-Idrissi Benhnia; Yolanda M Pacheco; Ezequiel Ruiz-Mateos; Manuel Leal
Journal:  Viral Immunol       Date:  2016-09-22       Impact factor: 2.257

5.  Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

Authors:  Sarah Lilian Pett; Janaki Amin; Andrejz Horban; Jaime Andrade-Villanueva; Marcelo Losso; Norma Porteiro; Juan Sierra Madero; Waldo Belloso; Elise Tu; David Silk; Anthony Kelleher; Richard Harrigan; Andrew Clark; Wataru Sugiura; Marcelo Wolff; John Gill; Jose Gatell; Martin Fisher; Amanda Clarke; Kiat Ruxrungtham; Thierry Prazuck; Rolf Kaiser; Ian Woolley; Juan Alberto Arnaiz; David Cooper; Jürgen K Rockstroh; Patrick Mallon; Sean Emery
Journal:  Clin Infect Dis       Date:  2016-04-05       Impact factor: 9.079

6.  Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.

Authors:  Nicholas I Paton; Wolfgang Stöhr; Alejandro Arenas-Pinto; Martin Fisher; Ian Williams; Margaret Johnson; Chloe Orkin; Fabian Chen; Vincent Lee; Alan Winston; Mark Gompels; Julie Fox; Karen Scott; David T Dunn
Journal:  Lancet HIV       Date:  2015-09-14       Impact factor: 12.767

7.  Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.

Authors:  Pedro Cahn; María José Rolón; María Inés Figueroa; Ana Gun; Patricia Patterson; Omar Sued
Journal:  J Int AIDS Soc       Date:  2017-05-09       Impact factor: 5.396

8.  Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

Authors:  S Lambert-Niclot; E C George; A Pozniak; E White; C Schwimmer; H Jessen; M Johnson; D Dunn; C F Perno; B Clotet; A Plettenberg; A Blaxhult; L Palmisano; L Wittkop; V Calvez; A G Marcelin; F Raffi
Journal:  J Antimicrob Chemother       Date:  2015-12-24       Impact factor: 5.790

9.  Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

Authors:  Jose I Bernardino; Amanda Mocroft; Patrick W Mallon; Cedrick Wallet; Jan Gerstoft; Charlotte Russell; Peter Reiss; Christine Katlama; Stephane De Wit; Laura Richert; Abdel Babiker; Antonio Buño; Antonella Castagna; Pierre-Marie Girard; Genevieve Chene; Francois Raffi; Jose R Arribas
Journal:  Lancet HIV       Date:  2015-09-30       Impact factor: 12.767

10.  Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens.

Authors:  P G Clay; S Nag; C M Graham; S Narayanan
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more
  5 in total

1.  Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.

Authors:  Santiago Jiménez de Ory; Carolina Beltrán-Pavez; Miguel Gutiérrez-López; María Del Mar Santos; Luis Prieto; Talía Sainz; Sara Guillen; David Aguilera-Alonso; Cristina Díez; Jose Ignacio Bernardino; María José Mellado; José Tomás Ramos; África Holguín; Marisa Navarro
Journal:  J Antimicrob Chemother       Date:  2021-06-18       Impact factor: 5.790

Review 2.  Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2018-11       Impact factor: 11.431

Review 3.  Effectiveness and Safety Analysis of PIs/r Based Dual Therapy in Treatment-Naïve, HIV/AIDS Patients: A Network Meta Analysis of Randomized Controlled Trials.

Authors:  Liu Hui; Han Xiaoxu; Wang Yuqi; Wang Peng; Wang Xin; Yi Yunyun; Li Xin
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

4.  Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.

Authors:  Jesús Troya; Carlos Dueñas; Idoia Irazola; Ignacio de Los Santos; Sara de la Fuente; Desiré Gil; Cristina Hernández; María José Galindo; Julia Gómez; Elisabeth Delgado; Estela Moreno-García; Guillermo Posada; Teresa Aldámiz; Jose Antonio Iribarren; José Manuel Guerra; Miguel Ángel Morán; Carlos Galera; Javier Fuente; Ana Peláez; Miguel Cervero; María Garcinuño; Marta Montero; Francisco Ceballos; Luis Buzón
Journal:  Medicine (Baltimore)       Date:  2022-06-17       Impact factor: 1.817

Review 5.  Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2020-01       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.